
Loading, please wait...

Loading, please wait...

ICU-ROX tested whether mechanically ventilated adults should receive a conservative oxygen strategy that limited exposure to high inspired oxygen concentrations compared with usual oxygen therapy. The trial included 1,000 critically ill adults expected to require mechanical ventilation beyond the first day. The conservative strategy reduced exposure to oxygen in some patients, but it did not significantly increase ventilator-free days or produce a clear mortality benefit. The findings are important because excessive oxygen can cause oxidative injury, yet the ideal oxygen target in critical illness is not defined simply by “lower is always better.” The study supports a more measured approach: clinicians should avoid unnecessary hyperoxia while maintaining adequate oxygen delivery and considering the underlying disease. Oxygen targets may need to differ in ARDS, cardiac arrest, traumatic brain injury, COPD and other conditions. ICU-ROX also demonstrates the difficulty of translating physiologic concerns into universally beneficial treatment thresholds. The practical takeaway is to treat oxygen like a drug—titrate it to a clinically meaningful target and reassess frequently rather than leaving high FiO2 settings unchanged. The trial therefore complements, rather than replaces, disease-specific evidence and reinforces the need for individualised oxygen therapy.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


ICU-ROX tested whether mechanically ventilated adults should receive a conservative oxygen strategy that limited exposure to high inspired oxygen concentrations compared with usual oxygen therapy. The trial included 1,000 critically ill adults expected to require mechanical ventilation beyond the first day. The conservative strategy reduced exposure to oxygen in some patients, but it did not significantly increase ventilator-free days or produce a clear mortality benefit. The findings are important because excessive oxygen can cause oxidative injury, yet the ideal oxygen target in critical illness is not defined simply by “lower is always better.” The study supports a more measured approach: clinicians should avoid unnecessary hyperoxia while maintaining adequate oxygen delivery and considering the underlying disease. Oxygen targets may need to differ in ARDS, cardiac arrest, traumatic brain injury, COPD and other conditions. ICU-ROX also demonstrates the difficulty of translating physiologic concerns into universally beneficial treatment thresholds. The practical takeaway is to treat oxygen like a drug—titrate it to a clinically meaningful target and reassess frequently rather than leaving high FiO2 settings unchanged. The trial therefore complements, rather than replaces, disease-specific evidence and reinforces the need for individualised oxygen therapy.
Today

The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back

A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back

Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back

A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back

A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back